Re-evaluating the role of Frat in Wnt-signal transduction

Cell Cycle

Volumn 4, Issue 8, 2005, Pages

  Van Amerongen, Renée ^a   Berns, Anton ^a,b  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Beta catenin; Frat; GBP; Glycogen synthesis kinase 3; GSK; Knockout; Mouse model; Wnt

Indexed keywords

BETA CATENIN; PROTEIN; PROTEIN FRAT; UNCLASSIFIED DRUG; WNT PROTEIN;

ENZYME ACTIVATION; EVALUATION; GENE TARGETING; GENETIC LINKAGE; NONHUMAN; ONCOGENE; PHOSPHORYLATION; PROTEIN BINDING; REVIEW; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; VERTEBRATE; XENOPUS;

VERTEBRATA;

EID: 25444513654     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: None     Document Type: Review

References (77)

1. Jonkers J, Berns A. Retroviral insertional mutagenesis as a strategy to identify cancer genes. Biochim Biophys Acta 1996; 1287:29-57.
2. Mikkers H, Berns A. Retroviral insertional mutagenesis: Tagging cancer pathways. Adv Cancer Res 2003; 88:53-99.
3. van Lohuizen M, et al. Identification of cooperating oncogenes in E mu-myc transgenic mice by provirus tagging. Cell 1991; 65:737-52.
4. van Lohuizen M, et al. Predisposition to lymphomagenesis in pim-1 transgenic mice: Cooperation with c-myc and N-myc in murine leukemia virus-induced tumors. Cell 1989; 56:673-82.
5. Mikkers H, et al. High-throughput retroviral tagging to identify components of specific signaling pathways in cancer. Nat Genet 2002; 32:153-9.
6. Jonkers J, Korswagen HC, Acton D, Breuer M, Berns A. Activation of a novel proto-oncogene, Frat1, contributes to progression of mouse T-cell lymphomas. EMBO J 1997; 16:441-50.
7. Jonkers J, Weening JJ, van der Valk M, Bobeldijk R, Berns A. Overexpression of Frat1 in transgenic mice leads to glomerulosclerosis and nephrotic syndrome, and provides direct evidence for the involvement of Frat1 in lymphoma progression. Oncogene 1999; 18:5982-90.
8. Jonkers J, et al. In vivo analysis of Frat1 deficiency suggests compensatory activity of Frat3. Mech Dev 1999; 88:183-94.
9. Chai JH, Locke DP, Ohta T, Greally JM, Nicholls RD. Retrotransposed genes such as Frat3 in the mouse Chromosome 7C Prader- Willi syndrome region acquire the imprinted status of their insertion site. Mamm Genome 2001; 12:813-21.
10. Kobayashi S, et al. Paternal expression of a novel imprinted gene, Peg12/Frat3, in the mouse 7C region homologous to the Prader-Willi syndrome region. Biochem Biophys Res Commun 2002; 290:403-8.
11. van Amerongen R, van der Gulden H, Bleeker F, Jonkers J, Berns A. Characterization and functional analysis of the murine Frat2 gene. J Biol Chem 2004; 279:26967-74.
12. Saitoh T, Katoh M. FRAT1 and FRAT2, clustered in human chromosome 10q24.1 region, are upregulated in gastric cancer. Int J Oncol 2001; 19:311-5.
13. Saitoh T, Mine T, Katoh M. Molecular cloning and expression of proto-oncogene FRAT1 in human cancer. Int J Oncol 2002; 20:785-9.
14. Saitoh T, et al. Molecular cloning and characterization of FRAT2, encoding a positive regulator of the WNT signaling pathway. Biochem Biophys Res Commun 2001; 281:815-20.
15. Lossos IS, et al. Transformation of follicular lymphoma to diffuse large-cell lymphoma: Alternative patterns with increased or decreased expression of c-myc and its regulated genes. Proc Natl Acad Sci USA 2002; 99:8886-91.
16. Gutmann DH, et al. Comparative gene expression profile analysis of neurofibromatosis 1-associated and sporadic pilocytic astrocytomas. Cancer Res 2002; 62:2085-91.
17. Lessnick SL, Dacwag CS, Golub TR. The Ewing's sarcoma oncoprotein EWS/FLI induces a p53-dependent growth arrest in primary human fibroblasts. Cancer Cell 2002; 1:393-401.
18. Yost C, et al. GBP, an inhibitor of GSK-3, is implicated in Xenopus development and oncogenesis. Cell 1998; 93:1031-41.
19. Li L, et al. Axin and Frat1 interact with dvl and GSK, bridging Dvl to GSK in Wnt- mediated regulation of LEF-1. Embo J 1999; 18:4233-40.
20. Weaver C, Kimelman D. Move it or lose it: Axis specification in Xenopus. Development 2004; 131:3491-9.
21. Moon RT, Kimelman D. From cortical rotation to organizer gene expression: Toward a molecular explanation of axis specification in Xenopus. Bioessays 1998; 20:536-45.
22. Larabell CA, et al. Establishment of the dorso-ventral axis in Xenopus embryos is presaged by early asymmetries in beta-catenin that are modulated by the Wnt signaling pathway. J Cell Biol 1997; 136:1123-36.
23. Farr IIIrd GH, et al. Interaction among GSK-3, GBP, axin, and APC in Xenopus axis specification. J Cell Biol 2000; 148:691-702.
24. Salic A, Lee E, Mayer L, Kirschner MW. Control of beta-catenin stability: Reconstitution of the cytoplasmic steps of the wnt pathway in Xenopus egg extracts. Mol Cell 2000; 5:523-32.
25. Miller JR, et al. Establishment of the dorsal-ventral axis in Xenopus embryos coincides with the dorsal enrichment of dishevelled that is dependent on cortical rotation. J Cell Biol 1999; 146:427-37.
26. Tao Q, et al. Maternal Wnt11 activates the canonical Wnt signaling pathway required for axis formation in Xenopus embryos. Cell 2005; 120:857-873.
27. Sumoy L, Kiefer J, Kimelman D. Conservation of intracellular Wnt signaling components in dorsal- Ventral axis formation in zebrafish. Dev Genes Evol 1999; 209:48-58.
28. Weaver C, et al. GBP binds kinesin light chain and translocates during cortical rotation in Xenopus eggs. Development 2003; 130:5425-36.
29. Thomas GM, et al. A GSK3-binding peptide from FRAT1 selectively inhibits the GSK3-Catalysed phosphorylation of axin and beta-catenin. FEBS Lett 1999; 458:247-51.
30. Nusse R. Wnt signaling in disease and in development. Cell Res 2005; 15:28-32.
31. Moon RT, Kohn AD, De Ferrari GV, Kaykas A. WNT and beta-catenin signalling: Diseases and therapies. Nat Rev Genet 2004; 5:691-701.
32. Dale TC. Signal transduction by the Wnt family of ligands. Biochem J 1998; 329(Pt 2):209-23.
33. Bax B, et al. The structure of phosphorylated GSK-3beta complexed with a peptide, FRAT tide, that inhibits beta-catenin phosphorylation. Structure (Camb) 2001; 9:1143-52.
34. Dajani R, et al. Structural basis for recruitment of glycogen synthase kinase 3beta to the axin-APC scaffold complex. Embo J 2003; 22:494-501.
35. Fraser E, et al. Identification of the Axin and Frat binding region of glycogen synthase kinase-3. J Biol Chem 2002; 277:2176-85.
36. Ferkey DM, Kimelman D. Glycogen synthase kinase-3 beta mutagenesis identifies a common binding domain for GBP and Axin. J Biol Chem 2002; 277:16147-52.
37. Cohen P, Frame S. The renaissance of GSK3. Nat Rev Mol Cell Biol 2001; 2:769-76.
38. Doble BW, Woodgett JR. GSK-3: Tricks of the trade for a multi-tasking kinase. J Cell Sci 2003; 116:1175-86.
39. Jope RS, Johnson GV. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci 2004; 29:95-102.
40. Sperber BR, Leight S, Goedert M, Lee VM. Glycogen synthase kinase-3 beta phosphorylates tau protein at multiple sites in intact cells. Neurosci Lett 1995; 197:149-53.
41. Beals CR, Sheridan CM, Turck CW, Gardner P, Crabtree GR. Nuclear export of NF-ATc enhanced by glycogen synthase kinase-3. Science 1997; 275:1930-4.
42. Embi N, Rylatt DB, Cohen P. Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. Eur J Biochem 1980; 107:519-27.
43. Morton S, Davis RJ, McLaren A, Cohen P. A reinvestigation of the multisite phosphorylation of the transcription factor c-Jun. EMBO J 2003; 22:3876-86.
44. Diehl JA, Cheng M, Roussel MF, Sherr CJ. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 1998; 12:3499-511.
45. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995; 378:785-9.
46. Ding VW, Chen RH, McCormick F. Differential regulation of glycogen synthase kinase 3beta by insulin and Wnt signaling. J Biol Chem 2000; 275:32475-81.
47. McManus EJ, et al. Role that phosphorylation of GSK3 plays in insulin and Wnt signalling defined by knockin analysis. EMBO J 2005; In press.
48. Frame S, Cohen P, Biondi RM. A common phosphate binding site explains the unique substrate specificity of GSK3 and its inactivation by phosphorylation. Mol Cell 2001; 7:1321-7.
49. Dajani R, et al. Crystal structure of glycogen synthase kinase 3 beta: Structural basis for phosphate-primed substrate specificity and autoinhibition. Cell 2001; 105:721-32.
50. Hagen T, Di Daniel E, Culbert AA, Reith AD. Expression and characterization of GSK-3 mutants and their effect on beta-catenin phosphorylation in intact cells. J Biol Chem 2002; 277:23330-5.
51. Liu C, et al. Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell 2002; 108:837-47.
52. Cho JH, Johnson GV. Glycogen synthase kinase 3beta phosphorylates tau at both primed and unprimed sites. Differential impact on microtubule binding. J Biol Chem 2003; 278:187-93.
53. Culbert AA, et al. GSK-3 inhibition by adenoviral FRAT1 overexpression is neuroprotective and induces Tau dephosphorylation and beta-catenin stabilisation without elevation of glycogen synthase activity. FEBS Lett 2001; 507:288-94.
54. Stoothoff WH, Cho JH, McDonald RP, Johnson GV. FRAT-2 preferentially increases glycogen synthase kinase 3 beta-mediated phosphorylation of primed sites, which results in enhanced tau phosphorylation. J Biol Chem 2005; 280:270-6.
55. Franca-Koh J, Yeo M, Fraser E, Young N, Dale TC. The regulation of glycogen synthase kinase-3 nuclear export by Frat/GBP. J Biol Chem 2002; 277:43844-8.
56. Hay E, et al. Interaction between LRP5 and Frat1 mediates the activation of the Wnt canonical pathway. J Biol Chem 2005; In press.
57. van Amerongen R, et al. Frat is dispensable for canonical Wnt signaling in mammals. Genes Dev 2005; 19:425-30.
58. Maretto S, et al. Mapping Wnt/beta-carenin signaling during mouse development and in colorectal tumors. Proc Natl Acad Sci USA 2003; 100:3299-304.
59. Greco TL, et al. Analysis of the vestigial tail mutation demonstrates that Wnt-3a gene dosage regulates mouse axial development. Genes Dev 1996; 10:313-24.
60. Hamblet NS, et al. Dishevelled 2 is essential for cardiac outflow tract development, somite segmentation and neural tube closure. Development 2002; 129:5827-38.
61. Zeng L, et al. The mouse Fused locus encodes Axin, an inhibitor of the Wnt signaling pathway that regulates embryonic axis formation. Cell 1997; 90:181-92.
62. Reva T, et al. A role for Wnt signalling in self-renewal of haematopoietic stem cells. Nature 2003; 423:409-14.
63. Reya T, et al. Wnt signaling regulates B lymphocyte proliferation through a LEF-1 dependent mechanism. Immunity 2000; 13:15-24.
64. Staal FJ, Clevers H. Tcf/Lef transcription factors during T-cell development: Unique and overlapping functions. Hematol J 2000; 1:3-6.
65. Okamura RM, et al. Redundant regulation of T cell differentiation and TCRalpha gene expression by the transcription factors LEF-1 and TCF-1. Immunity 1998; 8:11-20.
66. Sage J, Miller AL, Perez-Mancera PA, Wysocki JM, Jacks T. Acute mutation of retinoblastoma gene function is sufficient for cell cycle reentry. Nature 2003; 424:223-8.
67. Lijam N, et al. Social interaction and sensorimotor gating abnormalities in mice lacking Dvl1. Cell 1997; 90:895-905.
68. Long JM, LaPorte P, Paylor R, Wynshaw-Boris A. Expanded characterization of the social interaction abnormalities in mice lacking Dvl1. Genes Brain Behav 2004; 3:51-62.
69. Fujino T, et al. Low-density lipoprotein receptor-related protein 5 (LRP5) is essential for normal cholesterol metabolism and glucose-induced insulin secretion. Proc Natl Acad Sci USA 2003; 100:229-34.
70. Ruiz S, Segrelles C, Santos M, Lara MF, Paramio JM. Functional link between retinoblastoma family of proteins and the Wnt signaling pathway in mouse epidermis. Dev Dyn 2004; 230:410-8.
71. Hoeflich KP, et al. Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature 2000; 406:86-90.
72. Takada Y, Fang X, Jamaluddin MS, Boyd DD, Aggarwal BB. Genetic deletion of glycogen synthase kinase-3beta abrogates activation of IkappaBalpha kinase, JNK, Akt, and p44/p42 MAPK but potentiates apoptosis induced by tumor necrosis factor. J Biol Chem 2004; 279:39541-54.
73. Israsena N, Hu M, Fu W, Kan L, Kessler JA. The presence of FGF2 signaling determines whether beta-catenin exerts effects on proliferation or neuronal differentiation of neural stem cells. Dev Biol 2004; 268:220-31.
74. Zhou FQ, Zhou J, Dedhar S, Wu YH, Snider WD. NGF-induced axon growth is mediated by localized inactivation of GSK-3beta and functions of the microtubule plus end binding protein APC. Neuron 2004; 42:897-912.
75. Morfini G, Szebenyi G, Elluru R, Ratner N, Brady ST. Glycogen synthase kinase 3 phosphorylates kinesin light chains and negatively regulates kinesin-based motility. Embo J 2002; 21:281-93.
76. Benedito AB, et al. The transcription factor NFAT3 mediates neuronal survival. J Biol Chem 2005; 280:2818-25.
77. Lucas JJ, et al. Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J 2001; 20:27-39.